• hiPSC Intestinal Organoids for Pharmacokinetics

  2026-09-10

  Saito and colleagues developed a streamlined direct 3D culture strategy for generating expandable intestinal organoids from human induced pluripotent stem cells. The organoids can be propagated, cryopreserved, and converted into intestinal epithelial monolayers containing metabolically active enterocytes, providing a human-relevant platform for absorption, transporter, and drug-metabolism studies.

• Cardamomin, Oxidative Damage, and Ischemic Stroke

  2026-09-10

  This study identifies cardamomin from Amomum villosum stems and leaves as a protective agent in hydrogen peroxide-injured BV-2 cells and permanent cerebral ischemia in rats. Its main mechanistic contribution is linking MEK/ERK-dependent NRF2 activation with suppression of AIFM1-associated oxeiptosis, parthanatos, and DNA damage.

• miR-18a–ALOXE3 Control of GBM Ferroptosis

  2026-09-09

  The reference study identifies a miR-18a/ALOXE3 regulatory axis that links ferroptosis resistance with enhanced migration in glioblastoma. Its integrated cell, biochemical, and orthotopic mouse experiments suggest that lipid-oxidation biology is both a survival mechanism and a motility regulator in GBM, while also defining important questions for translating p53-related findings into cancer research.

• Milk-Derived EVs in Intestinal Stem Cell Models

  2026-09-09

  Wang et al. developed porcine intestinal stem cell models that distinguish how milk-derived extracellular vesicles access epithelial surfaces in different intestinal regions and organoid orientations. Their findings connect apical accessibility, endocytosis-sensitive uptake, and colon stem-cell responses, providing a physiologically relevant framework for intracellular trafficking research.

• Berbamine hydrochloride in Ferroptosis Research

  2026-09-08

  Use Berbamine hydrochloride as a practical pharmacological probe for linking STAT3, NF-κB, calcium homeostasis, and ferroptosis-associated phenotypes. This workflow combines dose-response testing in KU812 and HepG2 models with orthogonal viability, lipid-peroxidation, iron, and pathway assays.

• H-89 and the PKA–Metabolism Axis in Bone

  2026-09-08

  Wnt-driven bone formation depends on more than transcriptional activation: it also requires metabolic rewiring through a Ca2+-PKA-GFAT1–O-GlcNAcylation axis. This thought-leadership article explains how H-89, a cAMP-dependent protein kinase inhibitor, can help translational researchers test the PKA contribution while preserving appropriate controls, orthogonal validation, and realistic expectations for preclinical interpretation.

• WRN Loss, p53/PUMA, and MSI Colorectal Cancer

  2026-09-07

  This PNAS study explains why mismatch repair-deficient, microsatellite-instability colorectal cancer cells depend on Werner helicase: WRN loss activates a p53/PUMA apoptotic program. Genetic rescue experiments, pharmacological inhibition, xenografts, and patient-derived models support WRN as a therapeutic vulnerability, particularly in p53-wildtype MSI tumors.

• ATS-9R: Reliable Adipose Gene Delivery

  2026-09-07

  This scenario-driven guide explains how ATS-9R (Adipocyte-targeting sequence-9-arginine), SKU C8721, can improve experimental control in adipose-tissue gene delivery, viability, proliferation, and cytotoxicity workflows. It connects Prohibitin-mediated targeting with practical complexation parameters, assay controls, data interpretation, and evidence-based product selection.

• Renal OCT2/MATE1 Inhibition by 5-HT3 Antagonists

  2026-09-05

  George and colleagues established a comparative in vitro framework for testing five antiemetic 5-HT3 antagonists against the renal organic cation transporters OCT2 and MATE1. The results identify transporter-dependent differences in inhibitory potency and support closer evaluation of renal drug–drug interaction mechanisms involving cationic medicines.

• SB 431542: Selective ALK5 Inhibitor Guide

  2026-09-04

  SB 431542 is an ATP-competitive ALK5 inhibitor that suppresses TGF-β receptor signaling through Smad2 phosphorylation inhibition. Its ALK4 and ALK7 activity requires controlled experimental interpretation in fibrosis, glioma, stem-cell, and anti-tumor immunology research.

• TCEP Hydrochloride for Capture-and-Release Assays

  2026-09-04

  TCEP hydrochloride converts controlled disulfide cleavage into a practical tool for protein preparation, linker-release experiments, and assay optimization. Its water solubility and thiol-free handling make it a useful candidate for adapting capture-and-release lateral flow workflows, provided residual reductant and antibody integrity are carefully controlled.

• CCCP Mitochondrial Morphology Workflow Guide

  2026-09-03

  CCCP provides a controllable way to impose mitochondrial proton gradient disruption and test how living cells remodel their mitochondrial networks. This guide translates the urine-derived stem cell imaging strategy from a recent Alzheimer’s disease study into practical perturbation, imaging, AI-analysis, and troubleshooting workflows.

• Quercetin in LPS-Induced Depression: NLRP3 Findings

  2026-09-03

  A pre-proof study reports that quercetin improves depressive-like behavior and memory deficits in an LPS-induced mouse model while suppressing hippocampal NLRP3-associated neuroinflammation. Its main contribution is the integration of mood, cognition, microglial, and inflammasome-related endpoints, although translation to clinical antidepressant therapy remains preliminary.

• SARS-CoV-2 N Protein Sequesters GADD34 in Atypical Foci

  2026-09-02

  The 2024 Molecules study identifies a distinct SARS-CoV-2 immune-evasion mechanism in which nucleocapsid protein redirects GADD34 mRNA into atypical G3BP1-positive foci. This sequestration reduces GADD34 expression, impairs IRF3 nuclear localization and weakens interferon production, providing a mechanistic framework for studying stress-granule-dependent viral pathogenesis.

• Targeted SPP1 Inhibition in Tumor-Associated Macrophages

  2026-09-02

  The reference study develops a phenotypic screening and delivery strategy to reduce SPP1 expression in tumor-associated macrophages rather than treating SPP1 only as a prognostic marker. Its lead compound, CANDI460, was incorporated into a TAM-avid polymeric nanoconstruct and produced SPP1 suppression and tumor remission across murine models, providing a framework for macrophage-directed cancer research.

7999 records 1/534 page Next 12345 下5页 Last page